Prevalence of angiotensin-converting enzyme, methylenetetrahydrofolate reductase, Factor v Leiden, prothrombin and apolipoprotein e gene polymorphisms in Morocco

Annals of Human Biology

Volumn 37, Issue 6, 2010, Pages 767-777

  They They, Thierry Paluku ^a   Hamzi, Khalil ^a   Moutawafik, Mohamed Taha ^a   Bellayou, Hanane ^a   El Messal, Mariame ^b   Nadifi, Sellama ^a  

^a Faculté de Médecine et de Pharmacie   (Morocco)

^b FACULTÉ DES SCIENCES AIN CHOCK   (Morocco)

Author keywords

Cardiovascular risk factor; Genotyping; Moroccan population

Indexed keywords

BLOOD; CARDIOVASCULAR DISEASE; COAGULATION; ENZYME; GENETIC ANALYSIS; GENOTYPE; LIPID; METABOLISM; POLYMORPHISM; RISK FACTOR;

EID: 77958554933     PISSN: 03014460     EISSN: 14645033     Source Type: Journal    
DOI: 10.3109/03014461003738850     Document Type: Article

References (33)

1. 767-777 Bauduer F, Lacombe D. 2005. Factor V Leiden, prothrombin 20210a, methylenetetrahydrofolate reductase 677T, and population genetics. Mol Genet Metab 86:91-99.
2. Bayoumi RA, Simsek M, Taher MY, Sheela B, Alhinai A, Al-barwani H, Hassan MO. 2006. Insertion-deletion polymorphism in the angiotensine-converting enzyme (ACE) gene among Sudanese, Somalis, Emiratis, and Omanis. Hum Biol 78:103-108.
3. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, De Ronde H, Van der Velden PA, Reitsma PH. 1994. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369: 64-67.
4. Bouaziz L, Hézard N, Touhami M, Potron G, N'siri B, Guyen PN. 2004. Allelic frequency of the factor V Leiden mutation and of the prothrombin gene 20210A mutation in healthy Tunisian population. Thomb Haemost 91: 824-825.
5. Caprini JA, Glase CJ, Anderson CB, Hathaway K. 2004. Laboratory markers in the diagnosis of venous thromboembolism. Circulation 109:14-18.
6. Casas JP, Hingorani AD, Bautista LE, Sharma P. 2004. Meta-analysis of genetic studies in ischemic stroke: Thirty-two genes involving approximately 18000 cases and 58000 controls. Arch Neurol 61:1652-1662.
7. Cavalli-Sforza LL, Menozzi P, Piazza A. 1994. The history and geography of human genes. Princeton, NJ: Princeton University Press.
8. Cavalli-Sforza LL, Piazza A, Menozzi P, Montain J. 1988. Reconstruction of human evolution: Bringing together genetic, archeological and linguistic data. Proc Natl Acad Sci USA 85:6002-6006.
9. Corbo RM, Scacchi R. 1999. Apolipoprotein E (APOE) allele distribution in the world: Is APOE*4 a 'thrifty' allele? Ann Hum Genet 63:301-310.
10. Coudray C, Guitard E, Lemaire O, Cherkaoui M, Baali A, Hilali K, Sevin A, Kandil M, Harich N, Melhaoui M, Larrouy G, Moral P, Dugoujon JM. 2004. Les allotypes Gm des immunoglobulines chez les Berbères du Maroc. Antropo 6:63-69. www.didac.ehu.es/antropo.
11. Danneberg J, Abbes AP, Bruggeman BJ. 1998. Reliable genotyping of the G-20210A mutation of coagulation factor II (prothrombin). Clin Chem 44:349-351.
12. Donnelly LA, Palmer CNA, Whitley AL, Lang CC, Doney ASF, Morris AD, Donnan PT. 2008. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: A Go-DARTS study. Pharmacogenet Genomics 18:279-287.
13. Erdos E, Skidgel RA. 1987. The angioensin I-converting enzyme. Lab Invest 56:345-348.
14. Fadhlaoui-Zid K, Sanchez-Mazas A, Buhler S, Khodjet Ellkhill H, Ben Amor M, Comas D, Dugoujon JM, Slama H, Ammar Elgaaeid AB. 2009. Caracté risation génétique des isolats berbérophones du Sud tunisien par confrontation des résultats de trois marqueurs Polymorphes. Antropo 18:73-86.
15. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. 1995. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113.
16. Gandrille S, Alhenc-Gelas M, Aiach M. 1995. A rapid screening method for the factor V Arg506? Gln mutation. Blood Coagul Fibrinolysis 6:245-248.
17. Gialeraki A, Politou M, Loukianos R, Merkouri E, Markatos C, Kremastinos D, Travlou A. 2008. Prevalence of prothrombotic polymorphisms in Greece. Genet Test 12:541-547.
18. Hixson JE, Vernier DT. 1990. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 31:545-548.
19. Ioannidis JP, Ntzani EE, Trikalinos TA. 2004. Racial differences in genetic effects for complex diseases. Nat Genet 36:1243-1244.
20. Jurka J. 2004. Evolutionary impact of human Alu repetitive elements. Curr Opin Genet Devel 14:603-608.
21. Lahlali-Kacemi N, Bamou Y, Guedira A, Hassani M, Visvikis S, Siest G, Alami N, Kabbaj O, Lahrichi M. 2002. Polymorphisme de l'apolipoprotéine E dans une population marocaine: Fréquence allélique et relation avec les paramètres lipidiques plasmatiques. Ann Biol Clin 60:73-78.
22. Lane DA, Grant PJ. 2000. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 95:1517-1532.
23. Mathonnet F, Nadifi S, Serazin-Leroy V, Dakouane M, Giudicelli Y. 2002. Absence of Factor V Leiden mutation and low prothrombin G 20210 A mutation prevalence in a healthy Moroccan population. Thromb Haemost 88: 1073-1074.
24. Poort S, Rosendaal F, Reitsma P, Bertina R. 1996. A common genetic variation in the 3-ntranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698-3703.
25. Rahimy MC, Krishnamoorthy R, Ahouignan G, Laffan M, Vullialy T. 1998. The 20210 A allele of prothrombin is not found among sickle cell disease patients from west Africa. Thromb Haemost 79:444-445.
26. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. 1995. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 92:2800-2802.
27. Rigat B, Hubert C, Corvol P, Soubrier F. 1992. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP 1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 20:1433.
28. Rodriguez S, Gaunt TR, Day INM. 2009. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 169:505-514.
29. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Ernardi F, Cumming AM, Preston FE, Reitsma PH. 1998. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79:706-708.
30. Saidi S, Slamia LB, Ammou SB, Mahjoub T, Almawi WY. 2007. Association of apolipoprotein E gene polymorphism with ischemic stroke involving large-vessel disease and its relation to serum lipid levels. J Stroke Cerebrovasc Dis 16:160-166.
31. Shanmugam V, Sell KW, Saha BK. 1993. Mistyping ACE heterozygotes. Genome Res 3:120-121.
32. Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Redlund M. 2003. Geographical and ethnic variation of the 677C . Tallele of 5, 10 methylenetetrahydrofolate reductase (MTHFR): Findings from over 7000 newborns from 16 areas worldwide. J Med Genet 40:619-625.
33. Zivelin A, Rosenberg N, Faier S, Kornbrot N, Peretz H, Mannhalter C, Horellou MH, Seligsohn U. 1998. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood 92: 1119-1124.